循环肿瘤细胞的上皮-间质转化及CD133表达对甲状腺癌患者预后的预测作用

Epithelial-to-mesenchymal transition of circulating tumor cells and CD133 expression on predicting prognosis of thyroid cancer patients.

作者信息

Li Deyu, Li Na, Ding Ying

机构信息

Department of Nuclear Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan 450003, P.R. China.

Operating Room, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan 450003, P.R. China.

出版信息

Mol Clin Oncol. 2022 Aug 1;17(3):141. doi: 10.3892/mco.2022.2574. eCollection 2022 Sep.

DOI:10.3892/mco.2022.2574

PMID:36033974

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9403616/

Abstract

The present study aimed to explore the epithelial-to-mesenchymal transition of circulating tumor cells (CTCs) and CD133 expression in determining the prognosis of patients with thyroid cancer. It enumerated different CTC subtypes and analyzed CD133 gene expression in patients with thyroid cancer to evaluate the relationship between CTC number and thyroid cancer prognosis. In total 394 patients with thyroid cancer were enrolled. Among these, 270 cases had papillary thyroid cancer (PTC), 60 had follicular thyroid cancer (FTC), 30 had medullary thyroid cancer (MTC), 15 had poorly differentiated thyroid cancer, 19 had anaplastic thyroid cancer and 10 had non-malignant thyroid nodules based on their histopathological characteristics. CTC cell counts were determined by CanPatrol CTC capture technique before treatment. The present study also performed reverse transcription-quantitative PCR for CD133 gene expression and evaluated the relationship between CD133 expression and clinical pathology. A total of 330 cases of enrolled patients were classified as differentiated thyroid cancer, which included PTC and FTC. Their prognosis was excellent. The positivity rate of CTCs at diagnosis was 95.5%. The data of the present study showed that early recurrence and metastasis rates in PTC and FTC patients with >6 CTCs and positive mesenchymal circulating tumor cells (MCTCs) were significantly higher than those in patients with <6 CTCs and MCTCs. It was also found that those patients with >6 CTCs and MCTCs had shorter overall survival. In addition, CD133 levels in patients with thyroid cancer were strongly associated with the differentiation grades of thyroid cancers. The detection of >6 CTCs and positive MCTCs in patients with differentiated thyroid cancer was an excellent biomarker for predicting the prognosis of patients. CD133 expression was also identified as a good biomarker for thyroid cancer differentiation.

摘要

本研究旨在探讨循环肿瘤细胞（CTC）的上皮-间质转化及CD133表达在判定甲状腺癌患者预后中的作用。研究对不同的CTC亚型进行计数，并分析甲状腺癌患者的CD133基因表达，以评估CTC数量与甲状腺癌预后之间的关系。共纳入394例甲状腺癌患者。其中，根据组织病理学特征，270例为乳头状甲状腺癌（PTC），60例为滤泡状甲状腺癌（FTC），30例为髓样甲状腺癌（MTC），15例为低分化甲状腺癌，19例为未分化甲状腺癌，10例为非恶性甲状腺结节。治疗前采用CanPatrol CTC捕获技术测定CTC细胞计数。本研究还进行了CD133基因表达的逆转录-定量PCR，并评估了CD133表达与临床病理之间的关系。共330例纳入患者被归类为分化型甲状腺癌，包括PTC和FTC。其预后良好。诊断时CTC的阳性率为95.5%。本研究数据显示，CTC>6且间质循环肿瘤细胞（MCTC）阳性的PTC和FTC患者的早期复发和转移率显著高于CTC<6且MCTC阴性的患者。还发现，CTC>6且MCTC阳性的患者总生存期较短。此外，甲状腺癌患者的CD133水平与甲状腺癌的分化程度密切相关。检测分化型甲状腺癌患者CTC>6且MCTC阳性是预测患者预后的良好生物标志物。CD133表达也被确定为甲状腺癌分化的良好生物标志物。